Literature DB >> 3818951

Hereditary xanthinuria. Evidence for enhanced hypoxanthine salvage.

F A Mateos, J G Puig, M L Jiménez, I H Fox.   

Abstract

We tested the hypothesis that there is an enhanced rate of hypoxanthine salvage in two siblings with hereditary xanthinuria. We radiolabeled the adenine nucleotide pool with [8-14C]adenine and examined purine nucleotide degradation after intravenous fructose. The cumulative excretion of radioactivity during a 5-d period was 9.7% and 9.1% of infused radioactivity in the enzyme-deficient patients and 6.0 +/- 0.7% (mean +/- SE) in four normal subjects. Fructose infusion increased urinary radioactivity to 7.96 and 9.16 X 10(6) cpm/g creatinine in both patients and to 4.73 +/- 0.69 X 10(6) cpm/g creatinine in controls. The infusion of fructose increased total urinary purine excretion to a mean of 487% from low-normal baseline values in the patients and to 398 +/- 86% in control subjects. In the enzyme-deficient patients, the infusion of fructose elicited an increase of plasma guanosine from undetectable values to 0.7 and 0.9 microM. With adjustments made for intestinal purine loss, these data support the hypothesis that there is enhanced hypoxanthine salvage in hereditary xanthinuria. Degradation of guanine nucleotides to xanthine bypasses the hypoxanthine salvage pathway and may explain the predominance of this urinary purine compound in xanthinuria.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3818951      PMCID: PMC424217          DOI: 10.1172/JCI112893

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  THE STUDY OF PURINE UTILIZATION AND EXCRETION IN A XANTHINURIC MAN.

Authors:  J H AYVAZIAN; S SKUPP
Journal:  J Clin Invest       Date:  1965-07       Impact factor: 14.808

2.  Depletion of erythrocyte phosphoribosylpyrophosphate in man.

Authors:  I H Fox; J B Wyngaarden; W N Kelley
Journal:  N Engl J Med       Date:  1970-11-26       Impact factor: 91.245

Review 3.  Hypoxanthine-guanine phosphoribosyltransferase deficiency in gout.

Authors:  W N Kelley; M L Greene; F M Rosenbloom; J F Henderson; J E Seegmiller
Journal:  Ann Intern Med       Date:  1969-01       Impact factor: 25.391

4.  Studies on the mechanism of fructose-induced hyperuricemia in man.

Authors:  I H Fox; W N Kelley
Journal:  Metabolism       Date:  1972-08       Impact factor: 8.694

5.  An enzymatic basis for variation in response to allopurinol. Hypoxanthine-guanine phosphoribosyltransferase deficiency.

Authors:  W N Kelley; F M Rosenbloom; J Miller; J E Seegmiller
Journal:  N Engl J Med       Date:  1968-02-08       Impact factor: 91.245

6.  Allopurinol in the treatment of gout.

Authors:  R W Rundles; E N Metz; H R Silberman
Journal:  Ann Intern Med       Date:  1966-02       Impact factor: 25.391

7.  Urinary excretion of purines, pyrimidines and pyrazolopyrimidines in patients treated with allopurinol or oxipurinol.

Authors:  H A Simmonds
Journal:  Clin Chim Acta       Date:  1969-02       Impact factor: 3.786

8.  A direct colorimetric determination of uric acid in serum and urine with uricase-catalase system.

Authors:  N Kageyama
Journal:  Clin Chim Acta       Date:  1971-02       Impact factor: 3.786

9.  Study of purine metabolism in a xanthinuric female.

Authors:  M J Bradford; I H Krakoff; R Leeper; M E Balis
Journal:  J Clin Invest       Date:  1968-06       Impact factor: 14.808

10.  Effects of allopurinol and oxipurinol on purine synthesis in cultured human cells.

Authors:  W N Kelley; J B Wyngaarden
Journal:  J Clin Invest       Date:  1970-03       Impact factor: 14.808

View more
  14 in total

Review 1.  Inhibition of xanthine oxidase by allopurinol: a therapeutic option for ischaemia induced pathological processes?

Authors:  J G Puig; F A Mateos; V D Diaz
Journal:  Ann Rheum Dis       Date:  1989-11       Impact factor: 19.103

2.  Xanthine Oxidoreductase Function Contributes to Normal Wound Healing.

Authors:  Michael C Madigan; Ryan M McEnaney; Ankur J Shukla; Guiying Hong; Eric E Kelley; Margaret M Tarpey; Mark Gladwin; Brian S Zuckerbraun; Edith Tzeng
Journal:  Mol Med       Date:  2015-04-14       Impact factor: 6.354

3.  Xanthine oxidoreductase depletion induces renal interstitial fibrosis through aberrant lipid and purine accumulation in renal tubules.

Authors:  Toshio Ohtsubo; Kiyoshi Matsumura; Kanae Sakagami; Koji Fujii; Kazuhiko Tsuruya; Hideko Noguchi; Ilsa I Rovira; Toren Finkel; Mitsuo Iida
Journal:  Hypertension       Date:  2009-08-10       Impact factor: 10.190

4.  Purine metabolism in Lesch-Nyhan syndrome versus Kelley-Seegmiller syndrome.

Authors:  E A Mateos; J G Puig
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

Review 5.  Clinical and biochemical aspects of uric acid overproduction.

Authors:  J García Puig; F A Mateos
Journal:  Pharm World Sci       Date:  1994-04-15

Review 6.  A re-evaluation of the tissue distribution and physiology of xanthine oxidoreductase.

Authors:  A Kooij
Journal:  Histochem J       Date:  1994-12

7.  Adenosine triphosphate turnover in humans. Decreased degradation during relative hyperphosphatemia.

Authors:  M A Johnson; K Tekkanat; S P Schmaltz; I H Fox
Journal:  J Clin Invest       Date:  1989-09       Impact factor: 14.808

8.  Effects of uric acid dysregulation on the kidney.

Authors:  Lashodya V Dissanayake; Denisha R Spires; Oleg Palygin; Alexander Staruschenko
Journal:  Am J Physiol Renal Physiol       Date:  2020-03-30

Review 9.  Enzymatic Transition States and Drug Design.

Authors:  Vern L Schramm
Journal:  Chem Rev       Date:  2018-10-18       Impact factor: 60.622

Review 10.  Mutations associated with functional disorder of xanthine oxidoreductase and hereditary xanthinuria in humans.

Authors:  Kimiyoshi Ichida; Yoshihiro Amaya; Ken Okamoto; Takeshi Nishino
Journal:  Int J Mol Sci       Date:  2012-11-21       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.